Gilead Sciences (NASDAQ:GILD) Price Target Raised to $140.00 at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by Wells Fargo & Company from $120.00 to $140.00 in a report issued on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the stock. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target for the company. Bank of America reissued a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Barclays raised their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $104.24.

Gilead Sciences Trading Up 0.6 %

NASDAQ GILD opened at $115.44 on Wednesday. Gilead Sciences has a one year low of $62.07 and a one year high of $117.39. The company’s 50 day moving average price is $98.71 and its 200 day moving average price is $90.91. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market capitalization of $143.87 billion, a price-to-earnings ratio of 312.00, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts predict that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.74%. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 293,356 shares of company stock valued at $29,166,240. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors have recently modified their holdings of the stock. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.